Irritable Bowel Syndrome
Conditions
Keywords
irritable bowel syndrome, rectal hypersensitivity, probiotics, melatonin, brain-gut axis
Brief summary
Irritable bowel syndrome (IBS) is a very common chronic gastrointestinal disorder. Existing therapies for IBS are still far from satisfactory and new therapies are being constantly sought. Probiotics are promising candidate for the prevention and treatment of IBS. However, its efficacy and mechanism is still unclear. The current study aims to evaluate the effects of a combination probiotic, VSL#3, on symptoms and rectal sensitivity in patients with IBS. The underlying mechanism will also be investigated. We will recruit forty patients with Rome III IBS and randomized them, in a parallel group, double-blinded design, to take four VSL#3 capsules or placebos, twice daily, for six weeks. Before and after treatment, patients will be assessed for their symptoms, rectal sensitivity, as well as saliva and fecal melatonin levels. Bowel symptom diary and weekly satisfactory relief of bowel symptoms will also be recorded and evaluated.
Interventions
DIETARY_SUPPLEMENTVSL#3
Dose: 4 capsules of VSL#3 daily for 6 weeks.
DIETARY_SUPPLEMENTPlacebo
Identical looking preparation of placebo taken at the same dose regimen as the active comparator
Sponsors
National University Hospital, Singapore
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 68 Years
Healthy volunteers
No
Inclusion criteria
* Female and male patients with IBS between the ages of 18 and 68 will be recruited. IBS will be diagnosed according to the Rome III diagnostic criteria (Drossman and Dumitrascu, 2006). The history of previous chronic GI symptoms suggestive of IBS should be at least 3 months (not necessarily consecutive) over the preceding 6 months. The stool culture of each subject should be negative for hemoccult, pathogens (Salmonella and Shigella), parasites (Giardia) and ova/ cyst. Only patients who had IBS symptoms for at least one month prior to the study and whose IBS symptom score is of at least a moderate severity on at least one of IBS symptoms will be eligible for inclusion into the study.
Exclusion criteria
* Those subjects who are unwilling or unable to give informed consent, follow protocol or to stop all medications used to treat diarrhoea or colitis * Subject taking at the time of proposed enrolment any of the below listed prohibited medications: * Anticholinergics (dicyclomine, hyoscyamine, propantheline) * Cholinomimetic agents (bethanechol etc.) * All narcotics (morphine, codeine, propoxyphene either alone or in any * combination) * 5-HT3 receptor antagonists (e.g., alosetron, ondansetron, tropisetron, dolasetron, granisetron). * Gastrointestinal preparations: * Antacids (containing either magnesium or aluminium) * Antidiarrheal agents * Bismuth compounds * Laxatives (stimulant or osmotic) * Sulfasalazine * Treatment with immunosuppressive medications or presence of an immunocompromised state * If currently using medication (like those used in Diabetes mellitus, Sarcoidosis, Connective tissue disease, poorly controlled hypo/hyperthyroidism) may alter bowel motility or if under long term antibiotic therapy * Use of any other investigational drug and/or participation in any clinical trial within 3 months of entry to this study * Patients will be excluded if they had undergone previous abdominal surgery (except appendectomy, Caesarean section, Cholecystectomy, Tubal ligation, Hysterectomy, Hernia repair ≥ 6 months prior to enrolment) * Subject who has been diagnosed with any of the following GI disorders: * Inflammatory bowel disease (Crohn's disease, Ulcerative colitis, Indeterminate Colitis * Microscopic colitis (lymphocytic colitis, collagenous colitis) * Celiac Disease * Gastroparesis * Gastrointestinal obstruction and/or stricture * Chronic pancreatitis * Subject with a significant concomitant psychiatric, neurological, metabolic, renal, hepatic, infections, hematological, C.V or pulmonary illness, unless condition is stable and judged by the investigator that such condition does not interfere with the patients participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Resolution of symptoms | 6 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Rectal sensitivity | 6 weeks |
| Saliva and fecal melatonin levels | 6 weeks |
Countries
Singapore
Outcome results
None listed